121 related articles for article (PubMed ID: 2173004)
1. Pharmacological studies on the low molecular weight heparin derivative CY 216.
Kaiser B; Kühnemuth G; Markwardt F
Pharmazie; 1990 Jul; 45(7):522-4. PubMed ID: 2173004
[TBL] [Abstract][Full Text] [Related]
2. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
Kaiser B; Hauptmann J; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
[TBL] [Abstract][Full Text] [Related]
3. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulant and antithrombotic action of the synthetic thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine nitrile.
Kaiser B; Richter M; Hauptmann J; Markwardt F
Pharmazie; 1991 Feb; 46(2):128-31. PubMed ID: 1852761
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin.
Kaiser B; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):41-6. PubMed ID: 2459030
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of a low molecular weight butyryl heparin derivative (C4-CY 216) with long lasting effects.
Saivin S; Petitou M; Lormeau JC; Dupouy D; Sié P; Caranobe C; Houin G; Boneu B
Thromb Haemost; 1992 Mar; 67(3):346-51. PubMed ID: 1322569
[TBL] [Abstract][Full Text] [Related]
7. Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model.
Giedrojć J; Krupiński K; Breddin HK; Bielawiec M
Pol J Pharmacol; 1996; 48(3):317-22. PubMed ID: 9112669
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic and anticoagulant properties of synthetic polyanions: sulfated bis-aldonic acid amides.
Klauser RJ; Raake W; Meinetsberger E; Zeiller P
J Pharmacol Exp Ther; 1991 Oct; 259(1):8-14. PubMed ID: 1656031
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y
Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin.
Diness V; Nielsen JI; Pedersen PC; Wolffbrandt KH; Ostergaard PB
Thromb Haemost; 1986 Jun; 55(3):410-4. PubMed ID: 3750271
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Eriksson BI; Carlsson S; Halvarsson M; Risberg B; Mattsson C
Thromb Haemost; 1997 Nov; 78(5):1404-7. PubMed ID: 9408027
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic and thrombolytic activity of heparins in a rat model of laser-induced thrombosis.
Krupiński K; Giedrojć J; Breddin HK; Bielawiec M
Pol J Pharmacol; 1996; 48(3):345-50. PubMed ID: 9112675
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effects of heparin and related agents.
Hladovec J; Kornalík F
Cor Vasa; 1991; 33(1):68-74. PubMed ID: 1655354
[TBL] [Abstract][Full Text] [Related]
14. Comparative study on the antithrombotic effects of a synthetic thrombin inhibitor and of heparin in animal models.
Hauptmann J; Barth A; Schönberger FP; Markwardt F
Biomed Biochim Acta; 1983; 42(7-8):959-65. PubMed ID: 6651812
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration.
Rebello SS; Blank HS; Rote WE; Vlasuk GP; Lucchesi BR
J Pharmacol Exp Ther; 1997 Oct; 283(1):91-9. PubMed ID: 9336312
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin.
Cadroy Y; Harker LA; Hanson SR
J Lab Clin Med; 1989 Oct; 114(4):349-57. PubMed ID: 2551985
[TBL] [Abstract][Full Text] [Related]
17. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML
J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route.
Hiebert LM; Wice SM; Ping T; Herr D; Laux V
Thromb Haemost; 2001 Jan; 85(1):114-8. PubMed ID: 11204561
[TBL] [Abstract][Full Text] [Related]
19. Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.
Daykin HJ; Sturgeon SA; Jones C; Wright CE
Thromb Res; 2006; 118(6):755-62. PubMed ID: 16410020
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis.
Iacoviello L; D'Adamo MC; Pawlak K; Polishchuck R; Wollny T; Buczko W; Donati MB
Thromb Haemost; 1996 Dec; 76(6):1102-7. PubMed ID: 8972038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
